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Abstract 
Background: As malaria cases increase in some of the highest burden countries, more strategic deployment of new 
and proven interventions must be evaluated to meet global malaria reduction goals.
Methods: The cost and cost-effectiveness of indoor residual spraying (IRS) with pirimiphos-methyl (Actellic®300 CS) 
were assessed in a high transmission district (Mopeia) with high access to pyrethroid insecticide-treated nets (ITNs), 
compared to ITNs alone. The major mosquito vectors in the area were susceptible to primiphos-methyl, but resistant 
to pyrethoids. A decision analysis approach was followed to conduct deterministic and probabilistic sensitivity analy-
ses in a theoretical cohort of 10,000 children under five years of age (U5) and 10,000 individuals of all ages, separately. 
Model parameters and distributions were based on prospectively collected cost and epidemiological data from a 
cluster-randomized control trial and a literature review. The primary analysis used health facility-malaria incidence, 
while community cohort incidence and cross-sectional prevalence rates were used in sensitivity analyses. Lifetime 
costs, malaria cases, deaths and disability-adjusted life-years (DALYs) were calculated to determine the incremental 
costs per DALY averted through IRS.
Results: The average IRS cost per person protected was US$8.26 and 51% of the cost was insecticide. IRS averted 
46,609 (95% CI 46,570–46,646) uncomplicated and 242 (95% CI 241–243) severe lifetime cases in a theoretical children 
U5 cohort, yielding an incremental cost-effectiveness ratio (ICER) of US$400 (95% CI 399–402) per DALY averted. In 
the all-age cohort, the ICER was higher: US$1,860 (95% CI 1,852–1,868) per DALY averted. Deterministic and proba-
bilistic results were consistent. When adding the community protective effect of IRS, the cost per person protected 
decreased (US$7.06) and IRS was highly cost-effective in children U5 (ICER = US$312) and cost-effective in individuals 
of all ages (ICER = US$1,431), compared to ITNs alone.
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Background
Effective vector control programmes have direct health 
benefits by reducing vector-borne diseases burden and 
have increased labour productivity, economic devel-
opment; and strengthened health systems [1]. World-
wide reductions in malaria morbidity and mortality are 
largely due to the scale-up of vector control strategies 
for malaria prevention, mainly insecticide-treated nets 
(ITNs) and indoor residual spraying (IRS), as well as the 
introduction of effective therapies and reliable diagnostic 
tools [2]. As such, the continued reduction of the global 
malaria burden is successfully shrinking the geographical 
distribution of the disease [3] and has laid the foundation 
for recent malaria elimination initiatives [4].
Despite these gains, ten sub-Saharan African coun-
tries with the highest malaria burden, accounting for 
more than half of the global disease burden, registered an 
increase in the number of malaria cases in 2017. [5]. This 
increase jeopardizes the achievement of current malaria 
burden targets [6]. This trend reversal is in part explained 
by reduced malaria prevention coverage, reduced effec-
tiveness of pyrethroid insecticides used on ITNs due to 
increasing pyrethroid resistance among the primary 
malaria vectors, lack of political commitment, inade-
quate guidance to adapt new strategies in local settings 
of high burden countries, stagnation of investments and 
insufficient funds for malaria control and limited national 
cooperation across-sectors [7].
Optimizing the use of vector control interventions is 
one of the key tools to meeting global targets [6]. The 
effectiveness and cost-effectiveness of malaria vector 
control strategies are well documented [8, 9], and cur-
rently most sub-Saharan African countries recommend 
the implementation of either ITNs or IRS as preven-
tive measures in malaria risk regions, in alignment with 
World Health Organization (WHO) recommendations 
[5]. A key factor for the success of both interventions is 
the effectiveness of the insecticides applied. Despite their 
individual efficacy, few studies have evaluated the joint 
effect of both interventions [10–12], particularly in high 
transmission settings. Protopopoff et  al. [13], found no 
additional benefit of combining ITN and IRS when effec-
tive insecticides were used for both interventions, but 
evidence on the combined effectiveness is still incon-
clusive [14]. The WHO Guidelines for Malaria Vector 
Control recently declared the need to close this evidence 
gap with reliable economic and epidemiological data to 
determine the cost-effectiveness of different packages of 
vector control interventions to inform policy makers [1].
With around 10 million cases every year, representing 
5% of all malaria cases worldwide [5], Mozambique has 
one of the highest malaria burdens. This burden is het-
erogeneously distributed; while most parts of the central 
and northern provinces remain high transmission areas 
with prevalence of 70% and above in children under five 
years of age (U5), some districts in the southern prov-
inces have lower incidence and the prevalence is below 
1% in children U5 [15]. Approximately 66% of the popu-
lation in Mozambique has access to an ITN and 11% of 
households are covered by IRS [5]. A limited number 
of households benefit from the protective effect of both 
interventions simultaneously as the country has imple-
mented nationwide ITN campaigns and targeted IRS in 
high burden and pre-elimination areas. There is, how-
ever, insufficient data to inform the appropriateness and 
necessary scale of this combination in high-burden areas 
of the country.
Furthermore, emerging resistance to insecticides 
amongst mosquitoes might threaten vector control strat-
egies. The Mozambican Ministry of Health has confirmed 
vector resistance to pyrethroids, organochlorines, such as 
dichlorodiphenyltrichloroethane (DDT), and carbamates, 
but vectors remain susceptible to organophosphates [5]. 
In some districts of central Mozambique the main vector 
species, Anopheles gambiae and Anopheles funestus, had 
documented resistance to pyrethroids as early as 2010 
[16–19]. In this context, information on the effectiveness 
and cost-effectiveness of using new insecticides for vec-
tor control strategies is critical.
In order to address this evidence gap, a cluster-ran-
domized controlled trial was conducted from 2016 
to 2018 to assess the effectiveness of IRS with micro-
encapsulated pirimiphos-methyl (Actellic®300 CS) in 
addition to pyrethroid ITNs in the high-transmission 
district of Mopeia, central Mozambique, as compared 
to pyrethroid ITNs alone [20]. The primary vectors 
Conclusion: This study provides robust evidence that IRS with pirimiphos-methyl can be cost-effective in high trans-
mission regions with high pyrethroid ITN coverage where the major vector is susceptible to pirimiphos-methyl but 
resistant to pyrethroids. The finding that insecticide cost is the main driver of IRS costs highlights the need to reduce 
the insecticide price without jeopardizing effectiveness.
Trial registration: ClinicalTrials.gov identifier NCT02910934 (Registered 22 September 2016). https ://clini caltr ials.gov/
ct2/show/NCT02 91093 4?term=NCT02 91093 4&draw=2&rank=1
Keywords: Vector control, Indoor residual spraying, Insecticide-treated net, Economic evaluation, Mozambique
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in the areas are susceptible to pirimiphos-methyl and 
resistant to pyrethroids. The present study assessed the 
economic cost of the 2016 and 2017 IRS campaigns, as 
well as the cost-effectiveness of the combined effect of 
IRS and pyrethroid ITNs in Mopeia, as compared to 
pyrethroid ITNs alone.
Methods
Study design and description of interventions
The study was conducted from November 2016-Octo-
ber 2018 in Mopeia, central Mozambique, a rural dis-
trict with poor socio-economic indicators and in a 
high malaria burden province: 68% prevalence in chil-
dren U5 in 2015 [15, 21]. The population of the district 
in 2018 was 136,520 inhabitants. Anopheles funes-
tus sensu lato (s.l.) and, to a lesser extent An. funestus 
sensu stricto (s.s.) and An. gambiae s.l., are the domi-
nant local vectors. At baseline in 2017 An. gambiae s.l. 
was susceptible to pyrethroids and pirimiphos-methyl, 
but by 2018 there was emerging resistance in this vec-
tor to both alphacypermethrin and deltamethrin. 
There are no 2017 An. funestus s.l. data available, but 
An. funestus s.l. tested from Mopeia in 2018 were sus-
ceptible to DDT and pirimiphos-methyl but resistant 
to alphacypermethrin, deltamethrin and bendiocarb 
[22]. IRS with a microencapsulated formulation of the 
organophosphate insecticide pirimiphos-methyl was 
implemented in 43 IRS-assigned clusters in October–
November 2016 and 2017 to provide protection during 
the 2017 and 2018 high transmission seasons (Decem-
ber to April). The control group consisted of 43 clusters 
that did not receive IRS. The entire district, including 
the 86 study clusters [20], was covered by routine and 
campaign distribution of pyrethroid ITNs, receiving 
over one ITN per inhabitant in 2013 with baseline own-
ership across the district of 61–63% in 2016. Most of 
these ITNs at baseline had been distributed through 
antenatal care services and through a mass campaign 
in 2013. An additional 120,765 pyrethroid ITNs were 
distributed through a mass campaign in June-July 2017 
during study data collection, raising ownership to 90%. 
Additional details of the intervention, trial characteris-
tics and data collection can be found elsewhere [20].
The study received approved from the Institutional 
Review Board of the CISM (CIBS-CISM), the National 
Bioethical Committee (Comité Nacional de bioética para 
a Saúde de Moçambique, CNBS), and PATH’s Research 
Ethics Committee (REC) and was considered to be 
human subjects research with non-engagement by US 
Centers for Disease Control and Prevention (CDC) and 
approved by the US President’s Malaria Initiative (PMI) 
Operational Research Committee.
Decision analysis
A combination of decision analysis and life table analy-
sis were used to evaluate the cost-effectiveness of the 
combined effect of IRS and ITNs as compared to pyre-
throid ITNs alone on (1) a theoretical cohort of 10,000 
children U5 and, (2) a theoretical cohort of 10,000 indi-
viduals of all ages, followed over their lifetime, based on 
the Mozambican average life expectancy [10, 23]. For 
each cohort, lifetime costs and health effects associated 
to each study arm were compared. Each year each cohort 
was at risk of malaria according to the corresponding 
malaria infection incidence [22], and mortality rate [24], 
and individuals were taken out of the model based on a 
non malaria-related mortality rate [25]. Table 1 shows the 
input parameters used in the model, which were based 
on primary epidemiological impact data from the trial. 
Mortality and disability weight parameters were based 
on values and distributions obtained from peer-reviewed 
literature.
Annual frequency of malaria infection was estimated to 
result in an uncomplicated or severe episode according 
to the probability of disease severity extracted from the 
trial. Household and health system costs of malaria care 
for each uncomplicated and severe malaria case in this 
setting have been previously described [26] and are sum-
marized below under economic burden of malaria. The 
median age at study baseline (one year) was used for the 
theoretical cohort of children U5, and the most recent 
projected median age of the district population (15 years) 
was used for the theoretical all age cohort [21]. Migra-
tion from study site, malaria sequelae and other disease 
manifestations associated with malaria, such as anaemia, 
were disregarded due to lack of reliable data available in 
the district.
Health effects
Epidemiological data from the trial were used to assess 
the health effects of the IRS intervention (Table 1) [22]: 
IRS with pirimiphos-methyl in an area with high stand-
ard ITN coverage reduced malaria incidence measured 
at health facility by 22% in individuals of all ages, and 
by 24% in children U5. At community-level the reduc-
tion was lower: 18% in children U5. We used the malaria 
infection incidence associated with each study arm 
measured by monthly passive case surveillance records 
from health facilities and community health work-
ers to calculate the corresponding number of malaria 
cases and deaths for the two theoretical cohorts (10,000 
children U5 and 10,000 individuals of all ages), differ-
entiating between uncomplicated and severe malaria 
cases [22]. Due to the absence of reliable mortality data 
from the trial, we used malaria and non malaria-related 
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mortality rates reported for the country [24, 25]. Dis-
ability-adjusted life-years (DALYs) were further calcu-
lated for each study arm and target population. DALYs 
accounted for the accrual of malaria-related years of life 
lost and years lost due to disability for uncomplicated and 
severe malaria. DALYs were calculated using unweighted 
age-specific life expectancy [23], moderate and severe 
malaria-related disability weights reported by the Global 
Burden of Disease [27], and a 3% discount rate in accord-
ance with WHO guidance. The primary health outcomes 
were the number of DALYs averted for each theoretical 
cohort, while the secondary outcome measures were the 
Table 1 Input variables and associated confidence intervals and ranges used in the deterministic and probabilistic sensitivity analysis 
for the cost-effectiveness evaluation of vector control strategies in Mopeia, Mozambique
Children U5 children under five years of age, CI confidence interval, DALY disability-adjusted life-year, GDPpc gross domestic product per capita, HH household, HS 
health system, IQR inter-quartile range, IRS indoor residual spraying
Inputs Likeliest (Low–high) Probability distribution Source
Costs estimates (US$)
 IRS cost per person protected (Min–Max) 8.26 (7.25–9.27) Gamma Project data
Health system costs (IQR)
 HS—uncomplicated malaria 4.34 (4.32–4.35) Gamma [26]
 HS—severe malaria 36.97 (18.03–44.09) Gamma [26]
Household costs (all ages) (IQR)
 Uncomplicated malaria—HH direct cost 0.74 (0.05–0.19) Gamma [26]
 Uncomplicated malaria—HH indirect cost 16.67 (0.00–22.38) Gamma [26]
 Severe malaria—HH direct cost 3.54 (0.60–6.31) Gamma [26]
 Severe malaria—HH indirect cost 154.30 (31.45–87.71) Gamma [26]
Household costs (children U5) (IQR)
 Uncomplicated malaria—HH direct cost 0.92 (0.00–1.05) Gamma [26]
 Uncomplicated malaria—HH indirect cost 7.23 (0.00–5.90) Gamma [26]
 Severe malaria—HH direct cost 4.68 (1.99–6.31) Gamma [26]
 Severe malaria—HH indirect cost 61.23 (47.17–71.60) Gamma [26]
DALYs
 Discount rate (range) 0.03 (0.00–0.05) Point estimate Assumption
 Average age (all ages) 15 - Point estimate [21]
 Average age (children U5) 1 - Point estimate [22]
 Life expectancy at birth (95% CI) 57.07 (49.73–64.61) Lognormal [23]
 Length of disability: uncomplicated malaria (range) 0.01096 (0.00548–0.01644) Gamma Assumption
 Length of disability: severe malaria (range) 0.02739 (0.02054–0.03424) Gamma Assumption
 Disability weight: uncomplicated malaria (range) 0.051 (0.032–0.074) Lognormal [27]
 Disability weight: severe malaria (range) 0.133 (0.088–0.190) Lognormal [27]
Effects measurement
 % malaria cases severe (range) 0.00517 (0.00259–0.00776) Beta [22]
Malaria infection incidence (95% CI)
 Incidence rate ratio—health facility-based (all ages) 0.78 (0.77–0.79) Lognormal [22]
 Incidence rate ratio—health facility-based (children U5) 0.76 (0.75–0.78) Lognormal [22]
 Incidence rate ratio—community-based (children U5) 0.82 (0.79–0.86) Lognormal [22]
Malaria prevalence in 2018 (95% CI)
 Odds ratio (all ages) 0.70 (0.49–1.00) Lognormal [22]
 Odds ratio (children U5) 0.54 (0.31–0.92) Lognormal [22]
Mortality estimates (per 10,000 individuals) (range)
 Case fatality rate malaria (all ages) 0.000873 (0.000655–0.001091) Beta [24]
 Case fatality rate malaria (children under five) 0.005205 (0.003904–0.006506) Beta [24]
 Non-malaria mortality rate 0.0116 (0.0058–0.0174) Beta [25]
Others (US$)
 Threshold cost-effectiveness (3 times 2018 GDPpc) 1470.60 - Point estimate [35]
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number of malaria-related cases and deaths averted for 
the theoretical cohorts considered. Alternative epidemio-
logical data from the trial’s other methods were used for 
the sensitivity analyses: (1) malaria infection incidence 
from an active case surveillance at community level, and 
(2) malaria prevalence from the 2018 cross-sectional 
study [22]. Table 2 summarizes the malaria-related meas-
ures used in the current study.
Interventions costs
Abt Associates provided resources and costs incurred 
for IRS activities in Mopeia, which were prospectively 
collected for the two spray campaigns. Following an 
ingredient-based approach, all resources associated with 
spraying activities were classified and estimated [28]. 
Resources considered in the analysis included the per-
sonnel employed for spraying and monitoring activities 
in Mopeia, vehicle leasing and fuel, equipment, training 
and communication activities, commodities, the use of 
buildings, microplanning of activities, as well as salaries 
of personnel in Maputo and the US headquarters attrib-
utable to Mopeia. IRS was implemented in the study 
district and in six additional routine implementation dis-
tricts in Zambézia province by the President’s Malaria 
Initiative Africa IRS project (PMI AIRS) and the Mozam-
bican Ministry of Health with all financial costs paid for 
by PMI. Personnel, project management and monitoring 
and evaluation costs from headquarters in the United 
States, Mozambique and Zambézia central offices were 
allocated according to time devoted to Mopeia. The per-
centage of time spent in Mopeia for each year was calcu-
lated as the total number of structures sprayed in Mopeia 
divided by the total number of structures sprayed in all 
districts supported by PMI AIRS.
Insecticide was procured by the Government of 
Mozambique Global Fund grant with a co-payment by 
UNITAID through the NgenIRS partnership. The full 
insecticide economic cost paid by both the Global Fund 
and UNITAID was included in this analysis.
Spraying activities in Mopeia were coordinated from 
three operational bases within the district. There was a 
district-level warehouse and storekeeper, and a supervi-
sor and a storekeeper in each base. Spray teams included 
a team leader and five spray operators. Brigade supervi-
sors then coordinated and supervised brigades com-
prised of three teams. In addition to Ministry of Health 
staff who received per diems for their time working on 
the IRS campaign, Mopeia had one full-time PMI AIRS 
district coordinator. Salaries for the Ministry of Health 
staff were prorated based on the full-time equivalents 
allocated to the IRS campaigns. All other staffing related 
to the campaign were temporary hires: four storekeepers, 
three site supervisors, four brigade supervisors, 12 team 
leaders and 60 spray operators. Additionally, 12 commu-
nity mobilizers, two pump technicians, eight washers and 
five security guards supported the activities. Insecticide 
and other commodities were sent from the provincial 
capital to the district storehouse. In the district, two vehi-
cles covered the transport to operational sites and were 
also used to transport teams for spraying activities.
In addition to micro-costing of all materials and 
staffing related to implementation of the IRS cam-
paign, estimates also included the use of resources 
already in place that did not necessarily imply a direct 
payment from IRS, such as the district office rental; 
Table 2 Definition of malaria-related epidemiological measures used in the model
IRS indoor residual spraying
Health facility-based malaria incidence Calculated from confirmed malaria cases seeking care at public health facilities and community health 
workers in Mopeia, measured following an enhanced passive surveillance approach
Used in the main analysis for both cohorts
Community-based malaria incidence Calculated from an active cohort of children under five years of age at community level
Used in the univariate sensitivity analysis for the children under five cohort
Malaria prevalence Calculated in individuals of all ages for both study arms from the 2018 cross-sectional survey at the peak of 
the transmission season (April – May)
Used in the univariate sensitivity analysis for both cohorts
Severe malaria case Malaria case requiring hospital admission. Computed from the total number of malaria infected according 
to the malaria severity ratio obtained from the trial
Used in the main analysis for both cohorts
Uncomplicated malaria case Malaria case not requiring hospital admission
Malaria case fatality rate Malaria-associated case fatality rate estimated by the Global Burden of Disease (GBD) for the most current 
estimate (2017). Different estimates were used for the children under five and all age cohort
Used in the main analysis for both cohorts
IRS with community-wide protective effect IRS achieving high coverage (> 85%) so that the population target benefits from a “mass effect” on the 
vector population [33]
Used in the univariate sensitivity analysis for both cohorts
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thus capturing the economic costs of the programme 
[29]. The costs for all items procured in Mozambique 
were recorded in Mozambican meticais and later 
converted to United States dollars (US$) according 
to the official exchange rate [30]: 63.06 meticais/US$ 
in 2016 and 63.58 meticais/US$ in 2017. Quantities 
were inflated-adjusted [31] using the 2016 GDP defla-
tor (13.68%), and annualization of capital costs were 
subject to a standard discount rate of 3% [29, 32]. IRS 
costs were expressed as cost per (1) structure sprayed 
and, (2) person protected. We further computed the 
IRS cost per person protected adding the community-
wide protective effect, which considered the whole 
target population, due to the high coverage achieved 
(> 85%) [33]. Purchase and distribution costs of ITNs 
were not included in this analysis, as ITN ownership 
was not statistically different between study arms [22].
Economic burden of malaria
Households and health system costs associated with 
a malaria case have been previously described [26]. 
Households care-seeking costs included formal and 
informal care. Following a societal perspective, the 
costs of an uncomplicated and severe malaria case of 
each study arm were calculated as the lifetime sum-
mation of the health system and household costs asso-
ciated with malaria. Household costs were reported 
including (1) only household direct costs and, (2) 
direct and indirect household costs, which consid-
ered the time lost due to illness. Costs were expressed 
in 2018 US$ and discounted at a standard 3% rate to 
account for time preference.
Statistical analyses
The expected lifetime costs and malaria-related DALYs 
were calculated for each cohort, alongside the lifetime 
morbidity and mortality events associated with receipt 
of IRS and no IRS. Incremental cost-effectiveness ratios 
(ICERs) were calculated as the lifetime incremental costs 
divided by DALYs averted due to the IRS intervention in 
a context of high pyrethroid ITN coverage. Incremental 
costs were calculated as the summation of lifetime IRS 
costs in the IRS arm minus the lifetime cost savings due 
to a reduction of malaria burden between study arms. 
ICERs were calculated considering (1) household direct 
and indirect costs and, (2) only household direct costs. In 
accordance with recommendations from the WHO [34], 
the maximum level for which combining IRS and ITNs 
was considered cost-effective compared to ITNs alone 
was US$1,470.60 per DALY averted; three times the 2018 
Mozambican gross domestic product (GDP) per capita 
[35]. The highly cost-effective threshold was US$490.20 
per DALY averted (GDP per capita).
A deterministic cost-effectiveness analysis was con-
ducted using the most likely values of the parameters in 
the model. Uncertainty was incorporated by conducting 
a sensitivity analysis in which we evaluated univariate 
changes on ICERs due to changing the lower and higher 
values of key parameters (Table  3). Changes considered 
for sensitivity analyses in both cohorts included: (1) using 
the malaria prevalence obtained in 2018 from the cross-
sectional survey instead of using data on malaria inci-
dence from passive surveillance [22], (2) increasing and 
decreasing malaria incidence by 10% in individuals of 
all ages; (3) reducing the IRS cost per person protected 
to US$7.06 [36], due to adding the community-wide 
protective effect of achieving high IRS coverage [33], 
Table 3 Univariate sensitivity analysis: changes in selected parameters to account for uncertainty
Changes on the average health system costs associated with malaria are based on: (1) assuming no cost of screening fever (US$3.53) and higher commodity costs 
(US$5.12). Malaria prevalence rates from cross-sectional studies were used as alternative to health facility-based malaria incidence rates in the main analysis
IRR malaria incidence risk ratio, IRS  indoor residual spraying, OR odd ratio (malaria prevalence rates calculated from both study arms)
Parameter Lower value Upper value Reference
Parameters changed for the cohort of children under five years of age (U5)
 IRS-arm malaria incidence: children U5 30% reduction IRR = 0.82 Assumption, [22]
 Malaria mortality rate (children U5) 20% reduction 20% increase Assumption
Parameters changed for both cohorts (children U5 and individuals of all ages)
 Malaria prevalence (instead of incidence) ORall = 0.70 and ORchildrenU5 = 0.54 [22]
 IRS-arm malaria incidence: all ages 10% reduction 10% increase Assumption
 IRS cost per person protected US$7.06 50% increase [36], assumption
 Malaria mortality rate (all ages) 6.134/10,000 10% increase [24], assumption
% severe malaria over all malaria cases 20% reduction 0.0122 Assumption, [37]
 Discount rate 0% 5% Assumption
 Health system cost—uncomplicated case US$3.54 US$5.12 [26]
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and increasing the IRS cost by 50%; (4) decreasing the 
malaria-related mortality rate in individuals of all ages to 
6.134/10,000 [24], and increasing it to 7.294/10,000 (10% 
increase); (5) reducing the percentage of severe malaria 
cases by 20% and increasing it to a severity rate of 0.0122 
[37]; (6) modifying the discount rate (0% and 5%) and; 
(7) modifying the health system costs by assuming no 
cost of screening fever (US$3.54) and applying higher 
malaria commodity costs (US$5.12) [26]. Additionally, 
changes for the children U5 cohort included: (1) reducing 
the IRS-arm incidence by 30%, and using the incidence 
obtained at community level by an active case surveil-
lance (incidence rate ratio = 0.82) [22]; and (2) increas-
ing and reducing malaria-related mortality rate in 20% in 
children U5. Tornado diagrams were used to represent 
these changes on the ICERs due to univariate sensitivity 
analyses.
A probabilistic approach was further adopted in which 
the model parameters followed probability distributions 
(Table 1). Parameters’ distributions were extracted from 
trial primary data or, in their absence, were constructed 
assuming between 25–50% increase/decrease in the 
range of the parameters’ most likely values. Monte Carlo 
simulations (10,000 iterations) were used to produce a 
point estimate and 95% CIs for the incremental costs, 
DALYs averted and ICERs. Incremental costs and DALYs 
averted were graphically represented in two-dimen-
sional cost-effective planes. Acceptability curves were 
employed to represent the probability of the IRS arm to 
be cost-effective depending on a theoretical willingness-
to-pay per DALY averted. MS Excel 2016 (Visual Basic 
for Applications) and Stata v15 (StataCorp) were used for 
data analysis.
Results
Indoor residual spraying (IRS) campaigns
The IRS campaigns, which covered half of the district of 
Mopeia, lasted 42 days in 2016 and 50 days in 2017 and 
sprayed a similar number of structures each year, almost 
17,000 sprayable structures (Additional file 1: Table S1). 
Most of the district families lived in a household made 
up by a single structure (75%), some lived in a space with 
two structures (18%), and the remaining lived in a house-
hold with three or more structures (7%). The most com-
mon materials used in wall construction were clay blocks 
(40%), wood (35%) and bricks (11%). The campaigns 
reached approximately 85% of the sprayable structures in 
the IRS arm.
The average total cost of IRS using pirimiphos-methyl 
in the district was US$607,122, and the 2017 campaign 
was more expensive (Table  4). Insecticide costs repre-
sented approximately half the total costs (51%). Other 
costs included project management (17%), personnel 
(6%), vehicles (10%), equipment (6%), monitoring and 
evaluation (3%), training (3%), other commodities (3%) 
and buildings (2%). The programme average cost per 
structure sprayed was US$36.28 per year, yielding an 
average cost per person protected of US$8.26 per year. 
The latter reduced to US$7.06 per person protected when 
considering the community-wide protective effect due to 
the high IRS coverage achieved [33].
Table 4 Inflation-adjusted costs of indoor residual spraying activities in the district of Mopeia in 2016 and 2017 (US$)
1  The value was computed as the total IRS cost divided by the total target population, as it was assumed that a community-wide effect would protect individuals of 
non-sprayed households due to the high coverage achieved in the campaigns (85%)
Average economic cost of 
IRS campaigns
2016 campaign 2017 campaign
% of total Economic cost % of total Economic cost % of total
Personnel 35,019.67 5.77% 32,275.28 5.81% 37,764.06 5.74%
Vehicles 60,299.66 9.93% 54,894.23 9.87% 65,705.10 9.98%
Equipment 39,048.14 6.43% 40,273.10 7.24% 37,823.19 5.75%
Training 16,595.22 2.73% 16,978.43 3.05% 16,212.02 2.46%
Insecticide 312,006.37 51.39% 263,430.58 47.38% 360,582.16 54.78%
Commodities 15,160.09 2.50% 17,295.04 3.11% 13,025.14 1.98%
Buildings 9,745.97 1.61% 8,945.52 1.61% 10,546.43 1.60%
Project management 100,453.00 16.55% 104,803.45 18.85% 96,102.55 14.60%
Monitoring and evaluation 18,793.48 3.10% 17,088.59 3.07% 20,498.37 3.11%
Total 607,121.61 555,984.21 100% 658,259.00 100%
Cost per structure sprayed 36.28 33.70 38.87
Cost per person protected 8.26 7.25 9.27
Cost per person protected with 
community-wide  effect1
7.06 6.23 7.89
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Cost‑effectiveness analyses
Using passive case surveillance and considering 
households’ direct and indirect costs, a deterministic 
cost-effectiveness analysis demonstrated that the com-
bination of IRS with pirimiphos-methyl and pyrethroid 
ITNs was highly cost-effective compared to ITNs alone 
in the children U5 cohort (ICER = US$404) but not for 
the cohort of individuals of all ages (ICER = US$1,822) 
(Additional file  2: Table  S2). The tornado diagrams 
(Fig.  1) confirmed that, amongst all parameters, the 
malaria infection incidence and the IRS cost per per-
son protected had the higher impact on ICERs. For 
the all-ages cohort, both (1) the decrease in the IRS 
cost per person protected to US$7.06, which incor-
porated the community-wide protective effect, or (2) 
a 15% reduction in the IRS-arm incidence rate, made 
the intervention cost-effective, compared to the use 
of standard ITNs alone. With these changes in the 
children U5 cohort, the intervention remained highly 
cost-effective. Univariate changes of the remaining key 
Table 5 Probabilistic cost-effectiveness results of the combined effect of indoor residual spraying (IRS) and insecticide-treated nets 
(ITNs) on a theoretical cohort of 10,000 (A) children under five years of age and (B) individuals of all ages
Results from the Monte Carlo simulations with 10,000 iterations using the parameter values and distributions specified in Table 1
Children U5 children under five years of age, CI  confidence interval, DALY  disability-adjusted life-year, ICER incremental cost-effectiveness ratio
*Implies that the combination of IRS with pirimiphos-methyl and pyrethroid itns is cost-effective compared to pyrethroid itns alone, according to the WHO-Choice 
threshold of three times the GDP per capita
**Implies the strategy is highly cost-effective
Theoretical cohort of children U5 Theoretical cohort of individuals of all ages
Point estimate 95% CI lower 95% CI upper Point estimate 95% CI lower 95% CI upper
Incremental costs = intervention costs—malaria cost savings
 Direct costs only 1,633,402.91 1,630,687.28 1,636,118.53 1,578,361.96 1,575,844.28 1,580,879.64
 Direct and indirect costs 1,128,662.46 1,125,185.47 1,132,139.45 1,138,624.72 1,135,000.29 1,142,249.14
Incremental effects
 Total cases averted 46,851 46,811 46,889 33,909 33,880 33,936
 Uncomplicated cases averted 46,609 46,570 46,646 33,734 33,706 33,760
 Severe cases averted 242 241 243 175 174 176
 Deaths averted 94 93 94 30 29 30
 DALYs averted 2,856.76 2,850.34 2,863.18 624.39 622.66 626.12
ICERs: incremental cost per DALY averted
 ICER—direct costs only 579.46* 577.86* 581.05* 2,578.68 2,570.55 2,586.80
 ICER—direct and indirect costs 400.32** 398.82** 401.82** 1,860.08 1,852.17 1,867.98
Fig. 1 Tornado diagrams showing results from univariate sensitivity analyses. Changes on the deterministic value of the incremental 
cost-effectiveness ratio (ICER) by changing the value of selected parameters when considering households’ direct and indirect costs (US$). Analyses 
consider: a children under five years of age (pre-adjustment ICER of US$403.92) and b individuals of all ages (pre-adjustment ICER of US$1,821.86). 
Changes on the selected parameters had no impact on ICERs in children under five years of age or individuals of all ages with the exception of 
changes on the efficacy of IRS with pirimiphos-methyl and the insecticide price, which made the intervention cost-effective in individuals of all 
ages. The vertical lines represent the maximum cost-effectiveness thresholds. DALY disability-adjusted life-year, IRS indoor residual spraying, OR odd 
ratio
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parameters did not result in changes in the cost-effec-
tiveness interpretation.
Probabilistic results, presented in Table 5, were consist-
ent with those obtained in the deterministic analysis. For 
the children U5 cohort, the expected lifetime incremental 
costs were US$1,128,663 (95% CI 1,125,186–1,132,140), 
which included indirect household costs, averting 46,609 
(95% CI 46,570–46,646) uncomplicated cases, 242 
(95% CI 241–243) severe cases and 94 (95% CI 93–94) 
deaths associated with malaria. The incremental costs 
were US$400 (95% CI 399–402) per DALYs averted and 
US$580 (95% CI 578–581) per DALY averted when dis-
regarding indirect household costs. Conversely, the inter-
vention was not cost-effective for the cohort of all ages: 
US$1,860 (95% CI 1,852–1,868) per DALY averted and 
US$2,579 (95% CI 2,571–2,567) per DALY averted with-
out indirect household costs. However, the combined 
effect of IRS and ITNs was able to avert 33,734 (95% CI 
33,706–33,760) uncomplicated cases, 175 (95% CI 174–
176) severe cases and 30 (95% CI 29–30) malaria deaths 
during the lifespan of the cohort.
A graphical representation of the incremental costs 
and DALYs averted can be found in Additional file  3: 
Fig. S1. Most of the iterations were concentrated below 
the threshold line in the cohort of children U5 and above 
the line in the cohort of individuals of all ages, denoting 
the probabilistic analysis was cost-effective only for the 
cohort of children U5. Considering households’ indirect 
costs, for a theoretical willingness-to-pay of US$1,470.60, 
the combination of IRS and ITNs was cost-effective 
compared to ITNs alone for 100% of the simulations in 
children U5, and 18% of them in individuals of all ages 
(Fig. 2). In children U5 the intervention was highly cost-
effective in 85% of the simulations for a theoretical will-
ingness-to-pay of US$490.20.
Discussion
These findings demonstrate that the combination of IRS 
with pirimiphos-methyl and ITNs with an insecticide to 
which vectors are resistant [38], can be highly cost-effec-
tive in high transmission settings amongst children U5, 
but not cost-effective amongst the all age population, as 
compared to ITNs alone. Sensitivity analyses, including 
using data from different study methods [22], confirmed 
that these results were relatively stable, but that reduc-
tions in IRS cost or increases in campaign effectiveness 
would influence the cost-effectiveness determination for 
both populations. IRS was highly cost-effective amongst 
Fig. 2 Cost-effectiveness acceptability curves for the cohort of children under five years of age and individuals of all ages. The curves graphically 
represent the probability of adopting IRS with pirimiphos-methyl under high pyrethroid insecticide-treated nets (ITNs) being cost-effective at 
specific willingness-to-pay values, compared to not adopting IRS with pirimiphos-methyl under high pyrethroid ITN coverage. The vertical lines 
correspond to the standard cost-effectiveness thresholds by the World Health Organization. CE cost-effectiveness, Children U5 children under five 
years of age, DALY disability-adjusted life-year, IRS indoor-residual spraying
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children U5 when calculated using data from the pas-
sive surveillance and remained cost-effective when using 
effectiveness data from the active case surveillance and 
the 2018 cross-sectional study. Importantly, the ICER 
reduced to US$312 per DALY averted when adding the 
community-wide protective effect of IRS (IRS cost per 
person protected of US$7.06) (Table  4). Conversely, the 
adoption of IRS with pirimiphos-methyl was not cost-
effective in individuals of all ages as the lower protective 
effect shown in the all-age impact data could not over-
come the high IRS cost per person protected in the dis-
trict. However, adding the community-wide protective 
effect of achieving high coverage would make the adop-
tion of IRS with pirimiphos-methyl cost-effective in the 
high transmission district of Mopeia (ICER = US$1,431).
This study found that the yearly organophosphate IRS 
campaigns in Mopeia achieved high coverage rates at a 
high cost (US$607,122), mostly due to the high insecti-
cide price, responsible for 51% of the total cost and the 
existence of relatively high overheads and allowances to 
allocate to the district. Hence, the average IRS cost per 
person protected in Mopeia (US$8.26) was amongst the 
highest compared with other non-adjusted estimates 
reported in the literature (Additional file  4: Table  S3) 
[9, 10, 29, 39–46]. However, this is one of the first stud-
ies reporting IRS cost of new insecticide products, which 
are considerably more expensive than products that have 
been phased out for environmental reasons or due to 
resistance, such as DDT and pyrethroids [47]. The IRS 
cost per person protected obtained in this study differed 
from the ones reported by PMI in Mozambique: US$6.68 
in 2016 and US$5.73 in 2017 [36]. Such differences can 
be explained by the total population covered. Despite the 
high coverage achieved, the denominator (~ 71,000 indi-
viduals) was lower than the one obtained for the seven 
districts sprayed in the province (1.7 million individu-
als); raising, thus, the marginal cost to protect one indi-
vidual in Mopeia. Increasing economies of scale emerge 
when IRS campaigns expand to larger administrative 
areas [9, 36], or are directly implemented by the Ministry 
of Health without more expensive partner involvement. 
Nevertheless, the finding that the IRS cost would need to 
be reduced to meet the cost-effectiveness threshold in the 
all-age population and that this is largely driven by the 
insecticide cost underscores the importance of initiatives 
to reduce both insecticide price and improve efficiency of 
delivery systems [48].
The present work is amongst the few studies that have 
evaluated the cost and cost-effectiveness of combining 
malaria control interventions within a resource-con-
strained setting, particularly in a setting where emergent 
resistance to pyrethroids has reduced the programmatic 
effectiveness of standard, pyrethroid only ITNs. Thus, 
comparisons with other published works require cau-
tion. Based on other peer-reviewed studies published 
from 2000–2010, White et  al., estimate a significantly 
lower ICER per DALY averted for bed nets (US$27, range 
US$8.15-US$110) and IRS (US$143, range US$135-
US$150), but no combined ICER was reported due to lack 
of evidence [9]. A recent clinical trial in Ethiopia, which 
followed a similar methodological approach as this study, 
concluded that ITNs (ICER = US$207) dominated (were 
more cost-effective) than IRS, as well as their combined 
effect (ICER = US$1,403) in a low malaria transmission 
setting [10]. In Tanzania the estimation of a nation-wide 
implementation of IRS on top of nets reached an ICER 
of US$152.36 per malaria case averted compared to nets 
alone [11], which was not dissimilar to our ICER per 
DALY averted in children U5 when adding the commu-
nity-wide protective effect of IRS. This evidence should 
be considered by donors, international organizations and 
national governments, along with entomological insecti-
cide resistance data to inform a more efficient allocation 
of resources of current malaria control strategies.
This study utilizes rigorous prospective data to deter-
mine the parameter values and to conduct extensive sen-
sitivity analyses. However, it is not exempt of important 
limitations. First, the study did not include complications 
related to malaria, such as anaemia or cerebral malaria, 
which would have affected the ICERs and cost-effective-
ness outcomes. Second, a recent evaluation showed no 
added benefit of employing IRS with pirimiphos-methyl 
on top of ITNs with piperonyl butoxide [13]. Similarly, 
Kafy et  al., showed that malaria incidence was reduced 
when adding IRS using carbamates but not pyrethroids 
on top of standard ITNs in an area with pyrethroid-resist-
ant vectors [49]. The cost-effectiveness of IRS in relation 
to newer ITN products is an important area for future 
investigation. Third, this study used the standard GDP 
per capita thresholds to determine cost-effectiveness. 
However, more conservative approaches incorporat-
ing health opportunity costs would result in a maximum 
threshold of US$155 in Mozambique [50]. Under these 
thresholds, the adoption of IRS with pirimiphos-methyl 
would require a sustained and substantial price reduction 
beyond the lifespan of the NgenIRS partnership.
Conclusions
This study provides evidence on the cost-effectiveness 
of adopting IRS with an effective insecticide, pirimi-
phos-methyl, in high-burden regions with high access 
to standard ITNs and pyrethroid resistance. Consist-
ent with findings from other studies, this study illus-
trates the importance of delivering effective insecticides 
at high coverage for effective malaria control. However, 
the adoption of such a strategy in these settings should 
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be accompanied by efforts to maintain reductions in the 
insecticide price, which is the main driver of IRS costs. 
These findings provide important evidence to inform 
global and national policies on how to implement vec-
tor control interventions to accelerate progress towards 
meeting global malaria targets.
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